Viemed Healthcare (NASDAQ:VMD) Rating Lowered to “Buy” at Wall Street Zen
by Michael Walen · The Markets DailyViemed Healthcare (NASDAQ:VMD – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.
A number of other research firms have also weighed in on VMD. Weiss Ratings raised shares of Viemed Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, August 3rd. Freedom Capital cut Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.
Viemed Healthcare Price Performance
NASDAQ VMD opened at $9.20 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.13 and a debt-to-equity ratio of 0.04. The company has a fifty day moving average of $11.10 and a two-hundred day moving average of $9.83. The firm has a market capitalization of $350.43 million, a price-to-earnings ratio of 25.56 and a beta of 1.10. Viemed Healthcare has a 52 week low of $6.05 and a 52 week high of $12.61.
Viemed Healthcare (NASDAQ:VMD – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05). Viemed Healthcare had a net margin of 4.81% and a return on equity of 10.16%. The firm had revenue of $78.10 million during the quarter, compared to analysts’ expectations of $78.00 million. On average, analysts predict that Viemed Healthcare will post 0.42 earnings per share for the current year.
Insider Transactions at Viemed Healthcare
In other news, insider William Frazier sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $11.72, for a total value of $117,200.00. Following the transaction, the insider directly owned 73,214 shares in the company, valued at approximately $858,068.08. This represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Timothy Smokoff sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $11.50, for a total transaction of $230,000.00. Following the completion of the transaction, the director directly owned 75,518 shares in the company, valued at $868,457. This represents a 20.94% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 20.60% of the company’s stock.
Hedge Funds Weigh In On Viemed Healthcare
A number of institutional investors have recently modified their holdings of the stock. North Star Investment Management Corp. bought a new position in Viemed Healthcare in the first quarter worth approximately $921,000. Arrowstreet Capital Limited Partnership increased its holdings in Viemed Healthcare by 101.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 711,186 shares of the company’s stock worth $6,550,000 after purchasing an additional 358,863 shares during the period. Lazard Asset Management LLC raised its position in Viemed Healthcare by 117.6% during the 1st quarter. Lazard Asset Management LLC now owns 215,938 shares of the company’s stock valued at $1,989,000 after purchasing an additional 116,700 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in Viemed Healthcare during the 1st quarter valued at $1,834,000. Finally, Expect Equity LLC lifted its holdings in shares of Viemed Healthcare by 59.6% in the 4th quarter. Expect Equity LLC now owns 173,970 shares of the company’s stock worth $1,293,000 after buying an additional 64,961 shares during the period. 74.24% of the stock is owned by hedge funds and other institutional investors.
About Viemed Healthcare
Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.
Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.